These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 20099973)

  • 21. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis.
    Chang H; Li D; Zhuang L; Nie E; Bouman D; Stewart AK; Chun K
    Leuk Lymphoma; 2004 May; 45(5):965-9. PubMed ID: 15291356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Burden of cytogenetically abnormal plasma cells in light chain amyloidosis and their prognostic relevance.
    Kim SY; Im K; Park SN; Kim JA; Yoon SS; Lee DS
    Leuk Res; 2016 May; 44():45-52. PubMed ID: 27015231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.
    Kadam Amare PS; Jain H; Nikalje S; Sengar M; Menon H; Inamdar N; Subramanian PG; Gujral S; Shet T; Epari S; Nair R
    Indian J Med Res; 2016 Oct; 144(4):536-543. PubMed ID: 28256461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic abnormalities in monoclonal gammopathy of undetermined significance.
    Fonseca R; Bailey RJ; Ahmann GJ; Rajkumar SV; Hoyer JD; Lust JA; Kyle RA; Gertz MA; Greipp PR; Dewald GW
    Blood; 2002 Aug; 100(4):1417-24. PubMed ID: 12149226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases.
    Smadja NV; Leroux D; Soulier J; Dumont S; Arnould C; Taviaux S; Taillemite JL; Bastard C
    Genes Chromosomes Cancer; 2003 Nov; 38(3):234-9. PubMed ID: 14506697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
    Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chromosome 1q21 Aberrations Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients.
    Wang T; Geng C; Yang G; Zhou H; Zhang Z; Jian Y; Chen W
    J Clin Lab Anal; 2024 Sep; 38(17-18):e25072. PubMed ID: 39263925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
    Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
    Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolutionary sequence of cytogenetic aberrations during the oncogenesis of plasma cell disorders. Direct evidence at single cell level.
    Nagy Z; Kajtár B; Jáksó P; Dávid M; Kosztolányi S; Hermesz J; Kereskai L; Pajor L; Alpár D
    Leuk Res; 2011 Aug; 35(8):1114-6. PubMed ID: 21377730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Genetic abnormalities in multiple myeloma: role in oncogenesis and impact on survival].
    Decaux O; Lodé L; Minvielle S; Avet-Loiseau H
    Rev Med Interne; 2007 Oct; 28(10):677-81. PubMed ID: 17559979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
    Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
    J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation.
    Kim SY; Min HJ; Park HK; Oh B; Kim TY; She CJ; Hwang SM; Kim M; Kim HK; Kim I; Yoon SS; Park S; Kim BK; Lee JH; Lee DS;
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):810-20. PubMed ID: 21220034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cytoplasmic light-chain immunofluorescence combined with FISH in bone marrow smears to detect cytogenetic abnormalities in multiple myeloma].
    Shi Y; Yang H; Guo R; Guo Z; Li JY; Wu YJ; Qiu HR
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jun; 45(6):566-570. PubMed ID: 39134488
    [No Abstract]   [Full Text] [Related]  

  • 34. Plasma cell labeling index correlates with deletion of 13q14 in multiple myeloma.
    Li C; Chen L; Gao X; Qu X; Shen W; Yang R; Zhang R; Qiu H; Xu J; Lu H; Li J
    Leuk Lymphoma; 2011 Feb; 52(2):260-4. PubMed ID: 21133734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
    Nemec P; Zemanova Z; Greslikova H; Michalova K; Filkova H; Tajtlova J; Kralova D; Kupska R; Smetana J; Krejci M; Pour L; Zahradova L; Sandecka V; Adam Z; Buchler T; Spicka I; Gregora E; Kuglik P; Hajek R
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):548-54. PubMed ID: 20005965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.
    Grzasko N; Hajek R; Hus M; Chocholska S; Morawska M; Giannopoulos K; Czarnocki K; Druzd-Sitek A; Pienkowska-Grela B; Rygier J; Usnarska-Zubkiewicz L; Dytfeld D; Kubicki T; Jurczyszyn A; Korpysz M; Dmoszynska A
    Leuk Lymphoma; 2017 Sep; 58(9):1-15. PubMed ID: 28092996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization.
    Avet-Loiseau H; Brigaudeau C; Morineau N; Talmant P; Laï JL; Daviet A; Li JY; Praloran V; Rapp MJ; Harousseau JL; Facon T; Bataille R
    Genes Chromosomes Cancer; 1999 Jan; 24(1):9-15. PubMed ID: 9892103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma.
    Fonseca R; Debes-Marun CS; Picken EB; Dewald GW; Bryant SC; Winkler JM; Blood E; Oken MM; Santana-Dávila R; González-Paz N; Kyle RA; Gertz MA; Dispenzieri A; Lacy MQ; Greipp PR
    Blood; 2003 Oct; 102(7):2562-7. PubMed ID: 12805059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
    Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
    Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Correlation of chromosomal aberrations with prognostic markers in multiple myeloma patients--a single institution study].
    Lee JW; Lee JK; Hong YJ; Hong SI; Chang YH
    Korean J Lab Med; 2008 Dec; 28(6):413-8. PubMed ID: 19127104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.